Trastuzumab Deruxtecan (T-DXd) monotherapy + T-DXd, Durvalumab and Capecitabine Combination
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastric Adenocarcinoma
Conditions
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Trial Timeline
Jan 31, 2022 → Mar 31, 2029
NCT ID
NCT05034887About Trastuzumab Deruxtecan (T-DXd) monotherapy + T-DXd, Durvalumab and Capecitabine Combination
Trastuzumab Deruxtecan (T-DXd) monotherapy + T-DXd, Durvalumab and Capecitabine Combination is a phase 2 stage product being developed by Daiichi Sankyo for Gastric Adenocarcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05034887. Target conditions include Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma.
What happened to similar drugs?
5 of 20 similar drugs in Gastric Adenocarcinoma were approved
Approved (5) Terminated (3) Active (13)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05034887 | Phase 2 | Recruiting |
Competing Products
20 competing products in Gastric Adenocarcinoma